| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 06/20/2001 | CN1300295A Hybrid protein for inhibiting the deatanulation of mastocytes and the use thereof |
| 06/20/2001 | CN1300294A Frameshift mutants of beta-amyloid precursor protein and ubiquitin-B and their use |
| 06/20/2001 | CN1300285A Oxyiminoalkanoic acid derivatives |
| 06/20/2001 | CN1300282A Pyrazole derivatives as P-38 MAP kinase inhibitors |
| 06/20/2001 | CN1300278A Benzamide derivatives for the treatment of diseases mediated by cytokines |
| 06/20/2001 | CN1300277A Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them |
| 06/20/2001 | CN1300221A Treatment of cardiao hypertrophy |
| 06/20/2001 | CN1300220A Peptide compositions and formulations and use of same |
| 06/20/2001 | CN1300219A Epiallopregnanolone in the treatment of CNS disorders |
| 06/20/2001 | CN1300218A Folic acid-containing pharmaceutical compositions, and related methods and delivery systems |
| 06/20/2001 | CN1300217A New drug combinations of A N.A.R.I., preferably reboxetine, and pindolol |
| 06/20/2001 | CN1300212A Novel fatty analogues for the treatment of obesity, hypertension and fatty liver |
| 06/20/2001 | CN1300211A Novel fatty analogues for the treatment of premary and secondary restenosis |
| 06/20/2001 | CN1299681A Compound poultry lymphatic factor and its production process |
| 06/20/2001 | CN1299679A Arthralgia treating prescription |
| 06/20/2001 | CN1067389C Benzodihydropyran assorbic acid derivatives, their preparation and use |
| 06/20/2001 | CN1067385C Novel substituted piperidines useful for the treatment of allergic diseases |
| 06/20/2001 | CN1067384C Adhesion receptor antagonists, its preparation method and use as farm chemicals |
| 06/20/2001 | CN1067381C New 4-imidazolidinone compound, process for its preparation and pharmaceutical compositions which contain it |
| 06/20/2001 | CN1067270C Nutritions health care medicine |
| 06/20/2001 | CN1067269C Shenmei soft and hard capsule |
| 06/20/2001 | CN1067266C Shanshen Fengru Medicinal preparation and its production method |
| 06/19/2001 | US6248905 Oil-solubility; easily permeate into living tissues to release l-ascorbic acid, resulting in an exertion of the physiological action inherent to l-ascorbic acid. |
| 06/19/2001 | US6248882 Via dioxolane intermediates |
| 06/19/2001 | US6248864 Compounds and methods and modulating tissue permeability |
| 06/19/2001 | US6248791 Stimulating the differentiation of preadipocytic cells and therapies based thereon |
| 06/19/2001 | US6248787 Reducing cachexia |
| 06/19/2001 | US6248785 IL-8 receptor antagonists |
| 06/19/2001 | US6248780 Therapy for breast cancer |
| 06/19/2001 | US6248765 Imidazole derivatives as histamine receptor H3 (ANT) agonists |
| 06/19/2001 | US6248757 Antiserotonine agents |
| 06/19/2001 | US6248755 Antiinflammatory agents; antiallergens; autoimmune diseases |
| 06/19/2001 | US6248753 Bicyclic compounds |
| 06/19/2001 | US6248751 Inhibition of hair growth |
| 06/19/2001 | US6248749 Use of inhibitors of the activity of retinoic acid for treating sensit ive skin and/or acute damage induced by UV radiation |
| 06/19/2001 | US6248747 5-(heterocyclic alkyl)-6-aryl-dihydropyrimidines |
| 06/19/2001 | US6248739 Quinolinecarboxamides as antiviral agents |
| 06/19/2001 | US6248738 Isoquinolines as urokinase inhibitors |
| 06/19/2001 | US6248736 Dna polymerase inhibitors effective against herpesviruses |
| 06/19/2001 | US6248729 Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
| 06/19/2001 | US6248713 Cell adhesion inhibitors |
| 06/19/2001 | US6248576 Histidinol dehydrogenase |
| 06/19/2001 | US6248557 RatC |
| 06/19/2001 | US6248554 DNA sequence coding for a BMP receptor |
| 06/19/2001 | US6248532 Detecting modulators of regulatory element; incubate nucleotide sequences with modulators, monitor binding to nucleotide sequences, comparing binding in the presence and absence modulators |
| 06/19/2001 | US6248363 Improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutraceuticals, cosmeceuticals and diagnostic agents |
| 06/19/2001 | US6248341 Method of treating topical angiogenesis-related disorders |
| 06/19/2001 | US6248335 Ph control |
| 06/19/2001 | US6248326 Regulation of osteoclast formation by inhibition of osteoblastic stem cell factor |
| 06/19/2001 | CA2219050C Polyamine derivatives as radioprotective agents |
| 06/19/2001 | CA2218616C Nitrosylated neuropeptides |
| 06/19/2001 | CA2172187C Method of incorporating drugs into a polymer component of stents |
| 06/19/2001 | CA2040248C Method of inhibiting gastric acid secretion |
| 06/19/2001 | CA2028048C Derivatives of 1,4-dideoxy-1,4-imino-d-mannitol |
| 06/19/2001 | CA2027351C Emulsion of lipid containing a prostaglandin analogue |
| 06/19/2001 | CA1341260C Pharmaceutical and/or dietary compsitions containing l-carnitine and l- lysine |
| 06/14/2001 | WO2001042506A1 T1 receptor-like ligand ii and uses thereof |
| 06/14/2001 | WO2001042465A2 Chordin-like molecules and uses thereof |
| 06/14/2001 | WO2001042461A2 Apoptin-associating protein |
| 06/14/2001 | WO2001042459A1 Apoptosis inhibitory polypeptide, gene and polynucleotide encoding it and compositions containing the same |
| 06/14/2001 | WO2001042449A2 Methods for introducing genes into mammalian subjects |
| 06/14/2001 | WO2001042443A1 Method for modifying genetic characteristics of an organism |
| 06/14/2001 | WO2001042307A1 MUTANT ERα AND TEST SYSTEMS FOR TRANSACTIVATION |
| 06/14/2001 | WO2001042305A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001042301A1 Interferon-alpha induced gene |
| 06/14/2001 | WO2001042300A1 Process for producing functional silk fibroin and utilization of the same |
| 06/14/2001 | WO2001042288A2 G-protein coupled receptors |
| 06/14/2001 | WO2001042285A2 Extracellular matrix and cell adhesion proteins as well as genes encoding them |
| 06/14/2001 | WO2001042282A1 Depsipeptide and congeners thereof for use as immunosuppressants |
| 06/14/2001 | WO2001042281A1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/14/2001 | WO2001042273A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 06/14/2001 | WO2001042272A2 Eplerenone crystalline form exhibiting enhanced dissolution rate |
| 06/14/2001 | WO2001042267A1 Inducing cellular immune responses to mage2/3 using peptide and nucleic acid compositions |
| 06/14/2001 | WO2001042265A2 N6 heterocyclic 8-modified adenosine derivatives |
| 06/14/2001 | WO2001042252A1 New aminopropylphosphinic acids |
| 06/14/2001 | WO2001042246A2 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS |
| 06/14/2001 | WO2001042244A1 Novel 1,8-naphthyridin-2(1h)-one derivatives |
| 06/14/2001 | WO2001042241A1 Substituted pyridazines having cytokine inhibitory activity |
| 06/14/2001 | WO2001042231A2 Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors |
| 06/14/2001 | WO2001042222A1 Polymorphic crystalline forms of celecoxib |
| 06/14/2001 | WO2001042221A1 Solid-state form of celecoxib having enhanced bioavailability |
| 06/14/2001 | WO2001042215A1 4-pyridinyl-n-acyl-l-phenylalanines |
| 06/14/2001 | WO2001042213A1 Urea compounds having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042212A1 Carbamate derivatives having muscarinic receptor antagonist activity |
| 06/14/2001 | WO2001042207A2 Novel methods for the treatment and prevention of ileus |
| 06/14/2001 | WO2001042199A1 Amidinophenylpyruvic acid derivative |
| 06/14/2001 | WO2001042193A1 β2-ADRENERGIC RECEPTOR AGONISTS |
| 06/14/2001 | WO2001042192A2 Vla-4 integrin antagonists |
| 06/14/2001 | WO2001042191A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy |
| 06/14/2001 | WO2001041808A1 Medicinal compositions for oral use |
| 06/14/2001 | WO2001041807A2 Transmucosal composition containing a phosphodiesterase inhibitors for the treatment of erectile dysfunction |
| 06/14/2001 | WO2001041803A1 COMBINATION OF COMPOUNDS THAT INHIBIT THE BIOLOGICAL EFFECTS OF TNF-α AND CD95L IN A MEDICAMENT |
| 06/14/2001 | WO2001041792A1 Interleukin-1 receptor antagonist-like molecules and uses thereof |
| 06/14/2001 | WO2001041791A1 Contortrostatin (cn) and methods for its use in preventing metastasis and other conditions |
| 06/14/2001 | WO2001041780A2 Use of an immunosuppressant for increasing an antifugal activity of a lipopeptide |
| 06/14/2001 | WO2001041777A1 Calcium sorbefacients and process for producing the same |
| 06/14/2001 | WO2001041771A2 Transdermal system containing acetylsalicylic acid for treatment of migraine |
| 06/14/2001 | WO2001041769A2 Combination of cyamemazine and an atypical neuroleptic |
| 06/14/2001 | WO2001041768A2 Use of hymenialdisine or derivatives thereof in the manufacture of medicaments |
| 06/14/2001 | WO2001041766A1 The combination of a serotonin reuptake inhibitor and irindalone |